preparation for filing a Phase I IND application.
CD9 Cancer Stem Cell Program
- CD9 is more highly expressed in leukemia stems cells than normal
- Presented positive findings demonstrating the ability of the lead
anti-CD9 antibody to kill cancer stem cells in an in vivo model using
cells from human leukemia patients.
- Demonstrated ability to kill cancer stem cells while potentially
leaving normal cells alone.
CD63 Antibody Program
- Licensed to Genentech, Inc. in March 2006, the CD63 program continues
to advance in preclinical studies in a variety of cancer indications
as part of a program to move the lead antibody towards the clinic.
- Discovered and delivered novel antibodies to Takeda under the terms
of the research collaboration agreement, ARIUS has successfully met
its obligations to date and has received all scheduled research
payments from Takeda.
Additional Product Updates
- Currently, ARIUS has antibody programs targeting the MCSP antigen and
37LRP, in addition to several other undisclosed programs.
- Furthered lead optimization for antibodies covering additional novel
targets generated using ARIUS' proprietary FunctionFIRST(TM)
- Granted eight US patents for antibodies and one European patent to
date, and currently have 18 issued or allowed patents covering its
antibody programs and discovery platform and over 185 patents pending
- Promoted Susan Hahn, PhD to the position of Vice President of
- Appointed Mr. James Rae and Mr. Joseph Zakrzewski to its Board of
Directors and also appointed Mr. Carl Gordon a
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved